Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

On Friday, Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) reported a fourth quarter loss of -$5.32 per share for the period ended December 31, 2025, compared to a ...

ACXP shares are falling Thursday as overbought signals trigger a pullback after Wednesday's 108% rally. Read the full clinical update.

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Acurx Pharmaceuticals Inc shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session.

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting ...

Researchers at Tufts University School of Medicine are studying C. diff at multiple levels, from how individual bacterial ...

Visit CNNhealth.com, your connection for better living "Within a week," she recalled, "I was eating normally again." Scientists have known for decades that probiotics can boost your health. That's why ...